Fresenius Kabi has entered a global licensing agreement for the commercialisation of Polpharma Biologics鈥檚 vedolizumab biosimilar candidate PB016, except in the Middle East and North Africa.
An integrin receptor antagonist, Vedolizumab is a biologic therapy indicated for the treatment of ulcerative colitis and Crohn鈥檚 disease.
Under this agreement, Polpharma Biologics will lead the development and manufacturing of PB016 while Fresenius Kabi will have exclusive commercialisation rights globally, excluding the Middle East and North Africa.
Polpharma Biologics鈥檚 PB016 is a proposed biosimilar candidate referencing Takeda鈥檚 Entyvio, which is used to treat moderately to severely active ulcerative colitis and Crohn鈥檚 disease.
Polpharma Biologics group supervisory board member Konstantin Matentzoglu said: 鈥淭his partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally.鈥�
Matentzoglu further highlighted Fresenius Kabi鈥檚 expertise, saying: 鈥淔resenius Kabi鈥檚 deep commercialisation experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFresenius Kabi biopharma president Dr Sang-Jin Pak said: 鈥淭he in-licensing of PB016 from Polpharma Biologics underscores our commitment to expanding our autoimmune biosimilars portfolio and addressing the unmet needs of patients with chronic inflammatory diseases.鈥�
The deal is stated to build on Polpharma Biologics鈥� growing biosimilar portfolio. It has previously brought forward several biosimilars, such as ranibizumab and natalizumab, in collaboration with pharmaceutical entities across global markets.
This strategic alliance aims to enhance global access to affordable biologic medicines and support healthcare system sustainability. The partnership aligns with both companies’ commitments to expanding the availability of biologics worldwide.
Last October, Fresenius Kabi and Cellular Origins formed a partnership to advance the field of cell and gene therapy (CGT) by automating the manufacturing process.
